Quick Answer
Acumen Pharmaceuticals, Inc. reported Long Term Debt of $22.40 million for the year ending 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -23.9% in Long Term Debt from 2024 to 2025.
- This data is from Acumen Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $30.21 million | Q2 2024: $29.38 million | Q3 2024: $29.67 million | Q1 2025: $29.53 million | Q2 2025: $29.88 million | Q3 2025: $27.05 million.
- Historical annual values: Fiscal year 2025: $22.40 million | Fiscal year 2024: $29.42 million | Fiscal year 2023: $29.90 million | Fiscal year 2022: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: